Preclinical Targeted α- and β(−)-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies

HER2-targeted therapies have drastically improved the outcome for breast cancer patients. However, when metastasis to the brain is involved, current strategies fail to hold up to the same promise. Camelid single-domain antibody-fragments (sdAbs) have been demonstrated to possess favorable properties...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Puttemans, Janik, Dekempeneer, Yana, Eersels, Jos L., Hanssens, Heleen, Debie, Pieterjan, Keyaerts, Marleen, Windhorst, Albert D., van der Aa, Frank, Lecocq, Quentin, Breckpot, Karine, Morgenstern, Alfred, Bruchertseifer, Frank, Lahoutte, Tony, Devoogdt, Nick, D’Huyvetter, Matthias
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226418/
https://ncbi.nlm.nih.gov/pubmed/32326199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12041017
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars